Volume | 3,080 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
BioSig Technologies Inc | BSGM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.63 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
36 | 3,080 | - | 0.2619 - 16.50 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
06:13:29 | 41 | $ 1.58 | USD |
BioSig Technologies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
15.22M | 9.33M | - | 286k | -27.27M | -2.92 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
BioSig Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BSGM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.30 | 2.44 | 1.04 | 1.52 | 2,693,102 | -0.72 | -31.30% |
1 Month | 0.5181 | 2.98 | 0.4555 | 1.63 | 2,776,261 | 1.06 | 204.96% |
3 Months | 2.50 | 2.98 | 0.2619 | 1.37 | 1,317,522 | -0.92 | -36.80% |
6 Months | 5.80 | 6.80 | 0.2619 | 1.90 | 787,430 | -4.22 | -72.76% |
1 Year | 12.50 | 16.50 | 0.2619 | 5.66 | 652,386 | -10.92 | -87.36% |
3 Years | 39.90 | 45.80 | 0.2619 | 11.09 | 415,821 | -38.32 | -96.04% |
5 Years | 62.90 | 124.30 | 0.2619 | 33.78 | 416,679 | -61.32 | -97.49% |
BioSig Technologies Description
BioSig Technologiesis an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare¿s biggest priorities-saving time, saving costs, and saving lives. The Company¿s first product, the PURE EP¿ System, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The global EP market is projected to reach $16B in 2028 with an 11.2% growth rate. |